• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Director Pavell Jeff

    5/28/26 4:15:05 PM ET
    $HOTH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $HOTH alert in real time by email
    SEC FORM 4SEC Form 4
    FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number:3235-0287
    Estimated average burden
    hours per response:0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Pavell Jeff

    (Last)(First)(Middle)
    C/O ROCKET ONE INC., 720 MONROE STREET
    SUITE E514

    (Street)
    HOBOKEN NEW JERSEY 07030

    (City)(State)(Zip)

    UNITED STATES

    (Country)
    2. Issuer Name and Ticker or Trading Symbol
    Rocket One Inc. [ RKTO ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    XDirector10% Owner
    Officer (give title below)Other (specify below)
    2a. Foreign Trading Symbol
    3. Date of Earliest Transaction (Month/Day/Year)
    05/26/2026
    6. Individual or Joint/Group Filing (Check Applicable Line)
    XForm filed by One Reporting Person
    Form filed by More than One Reporting Person
    4. If Amendment, Date of Original Filed (Month/Day/Year)

    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeVAmount(A) or (D)Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
    Options$0.708305/26/2026A(1)75,00005/26/202605/26/2036Common Stock75,000$075,000D
    Explanation of Responses:
    1. The options were issued pursuant to the Rocket One Inc. Amended and Restated 2022 Omnibus Equity Incentive Plan, as amended, and vested in full upon grant.
    /s/ Hayley Springer as Attorney-In-Fact for Jeff Pavell05/28/2026
    ** Signature of Reporting PersonDate
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    * Form 4: SEC 1474 (03-26)
    Get the next $HOTH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HOTH

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $HOTH
    SEC Filings

    View All

    Hoth Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Rocket One Inc. (0001711786) (Filer)

    6/3/26 8:27:22 AM ET
    $HOTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hoth Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Rocket One Inc. (0001711786) (Filer)

    6/3/26 8:26:22 AM ET
    $HOTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Hoth Therapeutics Inc.

    424B5 - Rocket One Inc. (0001711786) (Filer)

    6/3/26 8:25:17 AM ET
    $HOTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HOTH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Hoth Therapeutics Becomes Rocket One Inc. (Nasdaq: RKTO), Targeting the Space Economy with Next-Generation Nanomagnetic AI Chip Technology and Ultra-Low-Power, Radiation-Tolerant Computing for Space and Defense Applications

    Company Adopts Space-Focused Identity, New Ticker "RKTO," and Exclusive License of AI Chip Architecture Designed for Ultra-Low-Power, Radiation-Tolerant Computing in Space and Defense ApplicationsHOBOKEN, N.J., May 27, 2026 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH) ("Hoth" or the "Company") today announced that, following the strategic repositioning disclosed on May 19, 2026, it has completed the legal change of its corporate name to Rocket One Inc. ("Rocket One") effective as of May 26, 2026 and will begin trading on The Nasdaq Capital Market under the new ticker symbol "RKTO" at the open of trading on May 28, 2026. The Company's common stock will cease trading under the symbol

    5/27/26 8:11:00 AM ET
    $HOTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hoth Therapeutics Awarded U.S. Patent for Cancer-Fighting HT-KIT Oncology Platform

    Allowed Claims Cover Composition-of-Matter and Methods Targeting MS4A6A Pre-mRNA Splicing to Reduce Surface Expression of the High-Affinity IgE Receptor (FcεRI); Strengthens Intellectual Property Foundation Underlying the HT-KIT Mast Cell ProgramHOBOKEN, N.J., May 26, 2026 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH) ("Hoth" or the "Company"), a clinical-stage biopharmaceutical company, today announced that the U.S. Patent and Trademark Office ("USPTO") has issued a Notice of Allowance for Hoth's HT-KIT therapeutic. The allowed claims cover antisense oligomers of 25 to

    5/26/26 8:18:00 AM ET
    $HOTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AI Chip Energy Efficiency: Hoth Therapeutics Restructures as Rocket One Inc. to Enter the AI Semiconductor Infrastructure Market with Acquisition of Exclusive Rights to Next Generation AI Semiconductor Acceleration Technology Built on Non-Volatile Nanomagnetic Semiconductor Architecture

    Company Targets Power Demands of AI Data Centers Through Patented Nanomagnetic Semiconductor and Spintronic Computing Technologies for AI, Defense, and Space ApplicationsHOBOKEN, N.J., May 19, 2026 /PRNewswire/ -- (NASDAQ:HOTH) ("Hoth" or the "Company") today announced that it intends to change its name to Rocket One, Inc. ("Rocket One"), and to restructure its business to position the Company, through its recently formed wholly-owned subsidiary, to pursue opportunities in artificial intelligence infrastructure, next-generation semiconductor technologies, and ultra-low-power AI computing.

    5/19/26 8:17:00 AM ET
    $HOTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HOTH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Linsley Wayne

    4 - Rocket One Inc. (0001711786) (Issuer)

    5/28/26 4:16:25 PM ET
    $HOTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by CEO and President Knie Robb

    4 - Rocket One Inc. (0001711786) (Issuer)

    5/28/26 4:15:59 PM ET
    $HOTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Sarnoff David

    4 - Rocket One Inc. (0001711786) (Issuer)

    5/28/26 4:15:42 PM ET
    $HOTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HOTH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO and President Knie Robb bought $16,750 worth of shares (25,000 units at $0.67), increasing direct ownership by 75% to 58,131 units (SEC Form 4)

    4 - Hoth Therapeutics, Inc. (0001711786) (Issuer)

    8/19/24 8:00:03 AM ET
    $HOTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HOTH
    Leadership Updates

    Live Leadership Updates

    View All

    Hoth Therapeutics to Spotlight HT-001 in Investor-Focused KOL Event Addressing Breakthrough Combating Cancer Treatment Skin Toxicities

    Company Expands IP Portfolio While Advancing Clinical Innovation in Oncology Supportive Care Case Study and Interim Clinical Trial Results Will Be Discussed NEW YORK, June 5, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a clinical-stage biopharmaceutical company pioneering breakthrough therapies to improve the lives of patients, today announced a Key Opinion Leader (KOL) event showcasing HT-001, its novel topical therapeutic, designed to treat debilitating skin toxicities caused by EGFR inhibitor cancer therapies. These common treatment-limiting side effects—suc

    6/5/25 8:12:00 AM ET
    $HOTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hoth Therapeutics Announces the Appointment of John Cirrito, PhD and Carla Yuede, PhD to Oversee Alzheimer's Therapeutic Program as Part of Hoth Scientific Advisory Board

    NEW YORK, Jan. 31, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a patient-focused biopharmaceutical company, today announced the addition of John Cirrito, PhD and Carla Yuede, PhD to the Company's Scientific Advisory Board. While serving on the Board, Dr. Cirrito and Dr. Yuede will oversee the development of HT-ALZ, an oral therapeutic in development under the 505(b)(2) regulatory pathway for the treatment of Alzheimer's disease (AD) and symptoms associated with AD. Mr. Robb Knie, CEO of Hoth Therapeutics, commented, "Hoth is extremely pleased to welcome Dr. Cir

    1/31/22 8:17:00 AM ET
    $HOTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HOTH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Hoth Therapeutics Inc. (Amendment)

    SC 13G/A - Hoth Therapeutics, Inc. (0001711786) (Subject)

    2/14/24 2:47:32 PM ET
    $HOTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Hoth Therapeutics Inc.

    SC 13G - Hoth Therapeutics, Inc. (0001711786) (Subject)

    2/14/23 12:55:35 PM ET
    $HOTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Hoth Therapeutics Inc. (Amendment)

    SC 13G/A - Hoth Therapeutics, Inc. (0001711786) (Subject)

    2/8/23 6:07:04 AM ET
    $HOTH
    Biotechnology: Pharmaceutical Preparations
    Health Care